Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for paclitaxel-induced peripheral neuropathy in women with breast cancer
IRCT20201115049390N1Phase 3Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of duloxetine in chemotherapy-induced peripheral neuropathy (CIPN) (4 arms), sponsored by Kashan University of Medical Sciences. Primary endpoint: Control of pain from paclitaxel-induced peripheral neuropathy. Started Nov 2020; status: completed.
02
Drugs
duloxetine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on IRCT20201115049390N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201115049390N1.